Shots:

• Alvotech to receive ~$45M as up front- equity investment- milestone while Yas Holding has acquired a 2.5% stake in Alvotech business and get rights to commercialize Alvotech’s three biosimilar candidates in MENA region
• The investment will complement Yas holding an existing portfolio and expands its footprints in health & pharmaceutical sector both in the MENA region and abroad
• Additionally- in Nov’2018- Fuji Pharma invest ~$50M for a 4.2% stake in the Alvotech and in Feb’2019 Fujipharma got exclusive rights to commercialize its biosimilar Ustekinumab (referencing Stelara) in Japan

Click here to­ read full press release/ article | Ref: Businesswire  | Image: Businesswire